Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XKDCT225
- Development stage
- Phase 1
- Lead developer
- Shenzhen Celconta Life Science
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Gene Therapies
- Administration
- Intravenous
01
Overview
XKDCT225 is an autologous, targeted chimeric antigen receptor T (CAR-T) cell therapy developed by Shenzhen Celconta Life Science for the treatment of advanced solid tumors that express Claudin18.2. The therapy involves engineering a patient's own T cells to express a CAR targeting Claudin18.2, a tight junction protein overexpressed in certain cancers such as gastric cancer, esophageal cancer, and gastroesophageal junction cancer. The mechanism of action is immunologic cytotoxicity via replacement and activation of T lymphocytes to recognize and kill tumor cells expressing Claudin18.2. As of early 2025, XKDCT225 is in Phase 1 clinical trials in China for patients with advanced solid tumors who have failed or are intolerant to standard treatments[1][2][4][7].
- Other names
- Autologous targeted claudin18.2 chimeric antigen receptor T cell injection
02
Targets
Claudin 18.2
Beyond the preview
Go deeper on XKDCT225.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XKDCT225.